Close Menu
Home › Melanoma BRAF Mutation Type May Affect Response to Targeted Treatments, Immunotherapy

Melanoma BRAF Mutation Type May Affect Response to Targeted Treatments, Immunotherapy

Jan 10, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Melanomas with different types of BRAF alterations appear to differ in their response to two treatment approaches, according to a new analysis appearing in Clinical Cancer Research today.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

What's Popular?

In Cancer

  1. Guardant Health Hopes Lung Cancer Stakeholder Alignment Will Help Advance Its Liquid Biopsy Goals

    Premium

  2. Inivata to Test Liquid Biopsy Against Tissue Sequencing in French Prospective Clinical Trial

  3. Survey of Precision Oncology Programs Finds Agreement on Testing, Divergence in Care Delivery

  4. Cancer Drug Discovery Firm Notable Nabs $40M in Series B Funding Round

  5. Helomics Inks Separate Pacts With UPMC, Interpace Dx for AI-Driven Oncology Decision Making

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.